BridgeBio Pharma, Inc. (BBIO) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Momentum 2.5/10 is below the 5.0 floor at $70.72 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Product: Attruby and Beyonttra; Earnings in 5 days (event risk).
BridgeBio Pharma is a commercial-stage biopharmaceutical company whose primary product Attruby (acoramidis) was FDA-approved in November 2024 for transthyretin amyloid cardiomyopathy, priced at $19,790 per 28-day supply in 2026. The company has treated 8,500+ patients with... Read more
Sell if holding. Momentum 2.5/10 is below the 5.0 floor at $70.72 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Product: Attruby and Beyonttra; Earnings in 5 days (event risk). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.4/10, moderate confidence.
Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.60, news boost analyst cluster(3), semi cycle peak clear). Fails on weak momentum and earnings proximity 5d<=7d. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductAttruby and Beyonttra10-K Item 1A: 'Our business is substantially dependent on the commercial success of Attruby and Beyonttra.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers·2 ceiling hits
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 2.5/10 is below the 5.0 floor at $70.72 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Product: Attruby and Beyonttra; Earnings in 5 days (event risk). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $66.30. Score 5.4/10, moderate confidence.
Take-profit target: $90.80 (+28.4% upside). Prior stop was $66.30. Stop-loss: $66.30.
Concentration risk — Product: Attruby and Beyonttra; Earnings in 5 days (event risk); Consecutive earnings misses (2).
BridgeBio Pharma, Inc. trades at a P/E of N/A (forward 134.5). TrendMatrix value score: 3.3/10. Verdict: Sell.
29 analysts cover BBIO with a consensus score of 4.3/5. Average price target: $101.
What does BridgeBio Pharma, Inc. do?BridgeBio Pharma is a commercial-stage biopharmaceutical company whose primary product Attruby (acoramidis) was...
BridgeBio Pharma is a commercial-stage biopharmaceutical company whose primary product Attruby (acoramidis) was FDA-approved in November 2024 for transthyretin amyloid cardiomyopathy, priced at $19,790 per 28-day supply in 2026. The company has treated 8,500+ patients with approved medicines and is advancing multiple Phase 3 rare disease programs. Beyonttra is commercialized in Europe via Bayer and in Japan via Alexion.